[1] |
Gilboa SM, Strickland MJ, Olshan AF, et al. Use of antihistamine medications during early pregnancy and isolated major malformations[J]. Birth Defects Res A Clin Mol Teratol, 2009, 85(2): 137⁃150. DOI: 10.1002/bdra.20513.
|
[2] |
Etwel F, Djokanovic N, Moretti ME, et al. The fetal safety of cetirizine: an observational cohort study and meta⁃analysis[J]. J Obstet Gynaecol, 2014, 34(5): 392⁃399. DOI: 10.3109/01443615.2014. 896887.
|
[3] |
So M, Bozzo P, Inoue M, et al. Safety of antihistamines during preg nancy and lactation[J]. Can Fam Physician, 2010, 56(5): 427⁃429.
|
[4] |
Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update[J]. Allergy, 2014, 69(7): 868⁃887. DOI: 10.1111/all.12313.
|
[5] |
Butler DC, Heller MM, Murase JE. Safety of dermatologic medica⁃tions in pregnancy and lactation: Part Ⅱ. Lactation[J]. J Am Acad Dermatol, 2014, 70(3): 417⁃427. DOI: 10.1016/j.jaad.2013.09. 009.
|
[6] |
Powell RJ, Leech SC, Till S, et al. BSACI guideline for the manage⁃ment of chronic urticaria and angioedema[J]. Clin Exp Allergy, 2015, 45(3): 547⁃565. DOI: 10.1111/cea.12494.
|
[7] |
Fitzsimons R, van der Poel LA, Thornhill W, et al. Antihistamine use in children[J]. Arch Dis Child Educ Pract Ed, 2015, 100(3): 122⁃131. DOI: 10.1136/archdischild⁃2013⁃304446.
|
[8] |
Choi SH, Baek HS. Approaches to the diagnosis and management of chronic urticaria in children[J]. Korean J Pediatr, 2015, 58(5): 159⁃164. DOI: 10.3345/kjp.2015.58.5.159.
|
[9] |
Potter P, Mitha E, Barkai L, et al. Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2⁃11 years[J]. Pediatr Allergy Immunol, 2016, 27(1): 55⁃61. DOI: 10.1111/pai.12460.
|
[10] |
American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults[J]. J Am Geriatr Soc, 2015, 63(11): 2227⁃2246. DOI: 10.1111/jgs.13702.
|
[11] |
Dávila I, del CA, Mullol J, et al. Use of second generation H1 antihistamines in special situations[J]. J Investig Allergol Clin Immunol, 2013, 23 Suppl 1: 1⁃16.
|
[12] |
Lasseter KC, Dilzer SC, Vargas R, et al. Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open⁃label study[J]. Clin Pharmacokinet, 2004, 43(2): 121⁃129. DOI: 10.2165/00003088⁃200443020⁃00004.
|
[13] |
Gupta SK, Kantesaria B, Wang Z. Multiple⁃dose pharmaco⁃kinetics and safety of desloratadine in subjects with moderate hepatic impairment[J]. J Clin Pharmacol, 2007, 47(10): 1283⁃1291. DOI: 10.1177/0091270007306561.
|
[14] |
Chen C. Physicochemical, pharmacological and pharmacokinetic properties of the zwitterionic antihistamines cetirizine and levocetirizine[J]. Curr Med Chem, 2008, 15(21): 2173⁃2191.
|
[15] |
Lucero ML, Gonzalo A, Mumford R, et al. An overview of bilastine metabolism during preclinical investigations[J]. Drug Chem Toxicol, 2012, 35 Suppl 1: 18⁃24. DOI: 10.3109/01480545.2012.682651.
|
[16] |
Church MK. Safety and efficacy of bilastine: a new H(1)⁃antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria[J]. Expert Opin Drug Saf, 2011, 10(5): 779⁃793. DOI: 10.1517/14740338.2011.604029.
|
[17] |
Noveck RJ, Preston RA, Swan SK. Pharmacokinetics and safety of ebastine in healthy subjects and patients with renal impairment[J]. Clin Pharmacokinet, 2007, 46(6): 525⁃534. DOI: 10.2165/00003088⁃200746060⁃00006.
|
[18] |
Thomson BK, Nolin TD, Velenosi TJ, et al. Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms[J]. Am J Kidney Dis, 2015, 65(4): 574⁃582. DOI: 10.1053/j.ajkd.2014.09.015.
|
[19] |
Noiri E, Ozawa H, Fujita T, et al. Pharmacokinetics of cetirizine in chronic hemodialysis patients: multiple⁃dose study[J]. Nephron, 2001, 89(1): 101⁃104. DOI: 10.1159/000046050.
|
[20] |
Shamizadeh S, Brockow K, Ring J. Rupatadine: efficacy and safety of a non⁃sedating antihistamine with PAF⁃antagonist effects[J]. Allergo J Int, 2014, 23(3): 87⁃95. DOI: 10.1007/s40629⁃014⁃0011⁃7.
|
[21] |
Sun H, Frassetto LA, Huang Y, et al. Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end⁃stage renal disease[J]. Clin Pharmacol Ther, 2010, 87(4): 465⁃472. DOI: 10.1038/clpt.2009.247.
|
[22] |
Verster JC, Mets MA. Psychoactive medication and traffic safety. Int J Environ Res Public Health, 2009, 6(3): 1041⁃1054.
|